Target Indication: Topical soft tissue infections
Stage: Preclinical – Entering Phase I in 2014
Chemistry: First in class small molecule <500MWT
Potency: MIC of <1.0µg/ml against multi-drug resistant Staph. aureus
Antibiotic spectrum: Gram positive MRSA, MSSA and Mupirocin resistant Staphylococci
Safety: Low toxicity and not able to enter the blood stream through topical application.
Efficacy: Efficacious in-vivo in Guinea Pig skin MRSA model demonstrating
Production: Low production costs (cheap and easy chemistry)
Mode of action: Addresses multiple targets
For more information please email: [email protected]